THrombolysis for Acute Wake-up and Unclear-onset Strokes With Alteplase at 0.6 mg/kg Trial (THAWS)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.
Also called NCT02002325
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 300 participants
- Registry
-
NCT02002325
-
- Other papers using this trial's data
- Associations between fluid-attenuated inversion recovery vessel hyperintensities and Alberta stroke program early CT score and clinical outcomes in stroke patients with unknown time of onset: A sub-analysis from a randomized controlled trial
- Magnetic Resonance Imaging-Guided Thrombolysis (0.6 mg/kg) Was Beneficial for Unknown Onset Stroke Above a Certain Core Size: THAWS RCT Substudy
- Thrombolysis With Alteplase at 0.6 mg/kg for Stroke With Unknown Time of Onset: A Randomized Controlled Trial
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Japan
- Registry status
- Unknown status
Technical summary
Registry record NCT02002325. Randomized; single masking; primary purpose treatment. Start 2014-05 (actual); primary completion 2019-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- THrombolysis for Acute Wake-up and Unclear-onset Strokes With Alteplase at 0.6 mg/kg Trial (THAWS)
- Acronym
- THAWS
- Condition
- Stroke
- Intervention (Drug)
- Tissue-type plasminogen activator (alteplase)
- Intervention (Other)
- Standard care
- Lead sponsor
- National Cerebral and Cardiovascular Center, Japan
- Collaborator
- Charitable Trust Mihara Cerebrovascular Disorder Research Promotion Fund
- Collaborator
- Japan Agency for Medical Research and Development
Record details
- Record id
cardio:ct-nct02002325- Content hash
e7e17ef89a9c279a5753a6421bf7105662482d13e8648ec067094df29b6bcae9